Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

NCT04902872 is registered in ClinicalTrials.gov with Cybrexa Therapeutics as lead sponsor.

NCT NCT04902872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04902872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Lead sponsor
Cybrexa Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
May 3, 2021
Completion date
June 24, 2025
Enrollment
69 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

appendix cancer, breast cancer, colorectal cancer, epithelial ovarian cancer, esophagus cancer, gastric cancer, non-small cell lung cancer, pancreas cancer, sarcoma, small cell lung carcinoma, solid tumor, adult, urothelial carcinoma